Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05CRG
|
|||
| Former ID |
DNC000842
|
|||
| Drug Name |
L-054852
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acromegaly [ICD-11: 5A60.0; ICD-10: E22.0; ICD-9: 253] | Investigative | [1] | |
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H43N5O2S
|
|||
| Canonical SMILES |
CC(C)C(NC(=O)C(C(C)C1=CNC2=CC=CC=C21)NC(=O)N3CCC4(CCC5=CC=CC=C54)CC3)SCCN
|
|||
| InChI |
1S/C32H43N5O2S/c1-21(2)30(40-19-16-33)36-29(38)28(22(3)25-20-34-27-11-7-5-9-24(25)27)35-31(39)37-17-14-32(15-18-37)13-12-23-8-4-6-10-26(23)32/h4-11,20-22,28,30,34H,12-19,33H2,1-3H3,(H,35,39)(H,36,38)
|
|||
| InChIKey |
UDRSIUYQZOTMRD-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Somatostatin receptor type 2 (SSTR2) | Target Info | Agonist | [1] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gastric acid secretion | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.